Column

Clinical Pathways GPS

How Clinical Pathways Can Support Bundled Payment Models

09/13/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

As the Blue Ribbon report of the Cancer Moonshot1 called for in 2016, we need to build the national cancer data ecosystem that is equal in dimension to the disease burden cancer imposes on society and the resources...

As the...

09/13/2018

Journal of Clinical Pathways

Editor's Page

Updating the Cancer Ecosystem: Access, Reimbursement, and Experience

09/13/2018

Winston Wong, PharmD, Editor-in-Chief

The advancements made in health care, and oncology care specifically, have improved treatment and patient care tremendously, and have the potential to make an even greater impact as care delivery becomes more...

The...

09/13/2018

Journal of Clinical Pathways

Business of Pathways

Blockchain, Data Obstruction, and the Promise of Information Sharing for a Value-Based Health Care World

09/13/2018

Ira Klein, MD, MBA, FACP—Column Editor

The current system of health care delivery and payment has tremendous inefficiencies that relate to an inability to share data among multiple parties, and from that sharing, glean useful and actionable information...

The...

09/13/2018

Journal of Clinical Pathways

Pharma Insights

Accreditation Explosion Among Top Specialty Pharmacy Trends

09/13/2018

Dominic Galante, MD, MS

Larry Blandford, PharmD—Column Editor

As the health care delivery system continues its transition to a value-based reimbursement model, pharmacies face many of the same market pressures as other health care providers to improve patient outcomes and...

As the...

09/13/2018

Journal of Clinical Pathways

Viewpoint

Precision Benefit Design: Using Clinical Benefit to Guide How Health Care Dollars Are Spent

09/13/2018

A Mark Fendrick, MD

Margaret Shope, BS

Successful implementation of precision medicine will need to address several system-wide challenges, including administrative complexities, the creation of new financing models, and aligning provider- and...

...

09/13/2018

Journal of Clinical Pathways

Counterpoint

Making Precision Benefit Design Patient-Centered

09/13/2018

Jason Shafrin, PhD

Precision benefit design is an extension of the concept of value-based insurance design (VBID), which aims to link patient benefit design and coinsurance to the likely benefit of a treatment net of its cost. Whereas...

...

09/13/2018

Journal of Clinical Pathways

Editor's Page

Balancing Costs and Patient Safety When Navigating New Regulations

08/22/2018

Winston Wong, PharmD, Editor-in-Chief

As new and exciting advancements in cancer drugs and care are made, updated guidance and regulations must follow. Oncologists and other stakeholders must keep up with the latest rules and regulations in order to...

As new...

08/22/2018

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Talking About Costs of Care During Shared Decision Making—Part One: The Problem

08/22/2018

Alan Balch, PhD—Column Editor

In Part 1 of this 2-part column series on shared decision making, we discuss the need for health care teams to create a safe and inviting environment for patients to talk about financial concerns and questions...

In...

08/22/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Communicating More Through Clinical Pathways to Advance Value-Based Health Care

08/22/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

The Food and Drug Administration (FDA) recently published guidance that clarifies how pharmaceutical manufacturers can share product information with payers while remaining compliant with FDA rules on...

The...

08/22/2018

Journal of Clinical Pathways

Counterpoint

CAR-T Therapies: Placing Patient Safety First

08/22/2018

Chadi Nabhan, MD, MBA, FACP

Bruce A Feinberg, DO

The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...

The...

08/22/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products